ueber-uns-two

Über uns

WER WIR SIND

Peppermint VenturePartners (PVP) investiert als privater Venture Capital Investor mit Sitz in Berlin in junge Unternehmen aus dem Gesundheitswesen.
PVP wurde 2008 von Ingeborg Neumann, Dr. Joachim Rautter und Dr. Klaus Stöckemann gegründet. Als Experten auf ihren Gebieten vereinen sie und ihr Team mehr als 40 Jahre Erfahrung in den Bereichen Venture Capital, Medizintechnik, Biotechnologie, Pharma und Gesundheitswesen.

i_

WEN WIR FINANZIEREN

In unserem Fokus stehen Firmen aus den Bereichen der Medizintechnik, Diagnostik und Digital-Health sowie Plattformtechnologien in der Biomedizin, die durch innovative Ideen herausstechen.
Sie sollten patentgeschützte Technologien und Produkte entwickeln oder neue Geschäftsmodelle im Gesundheitswesen anbieten. Bislang ungelöste medizinische Probleme zur Verbesserung der Diagnostik und Therapie von Erkrankungen bei gleichzeitiger Kosteneinsparung sollten im Visier der Jungunternehmer stehen, um für ein Investment durch PVP in Frage zu kommen.

WAS WIR ANBIETEN

Als engagierter Partner begleitet PVP alle wichtigen Schritte eines Unternehmens, von dessen Gründung bis hin zum strategischen Exit.
So unterstützt PVP beispielsweise die Gründer auch dabei, für die Umsetzung ihrer Idee das passende Management-Team aufzustellen.

UNSER AKTUELLER FONDS

Ende 2010 initiierte PVP in Zusammenarbeit mit der Stiftung Charité den Peppermint Charité Biomedical Fund (CBF 1).
Im Rahmen einer Partnerschaft mit der Charité -Universitätsmedizin Berlin verfügt PVP über ein einzigartiges Netzwerk medizinischer Expertise einer der größten und bedeutendsten Universitätskliniken in Europa und deren internationaler Partner.

WIR KOOPERIEREN MIT

Neben dem Management des CBF übernahm PVP 2011 im Auftrag der Helmholtz-Gemeinschaft die Verantwortung für das externe Management des neu aufgelegten Helmholtz Validierungsfonds (HVF).
Im Rahmen dieser Zusammenarbeit verfügt PVP über einen sehr guten Zugang zur größten Forschungsgemeinschaft in Deutschland.

UNSER PORTFOLIO

Seit Anfang 2011 hat sich der CBF an insgesamt sieben Unternehmen beteiligt und mit fünf Unternehmen ein vielversprechendes Portfolio im Bereich Medizintechnik und Digital Health aufgebaut.
Bis Ende 2016 sind bis zu vier weitere Investments geplant.
team

Team

Our team has many years of experience in building early-stage healthcare companies.

The combination of complementary skill sets and interdisciplinary technical expertise, in conjunction with a comprehensive national and international network in the healthcare sector, enables PVP to guide all of a company’s key stages of development, from start-up, and financing rounds through growth stages and strategic exits. Since the year 2000, PVP team members have been working in various constellations on various deals and exits.


 

INGEBORG NEUMANN

INGEBORG NEUMANN

MANAGING PARTNER View Details
Dr. Joachim Rautter

Dr. Joachim Rautter

MANAGING PARTNER View Details
Dr. Klaus Stöckemann

Dr. Klaus Stöckemann

Managing Partner View Details
Dr. Magnus Holm

Dr. Magnus Holm

Venture Partner View Details
Dr. Markus Müschenich

Dr. Markus Müschenich

Venture Partner View Details
SIMONE SCHÖPP

SIMONE SCHÖPP

CONTROLLING View Details
Henriette Braun

Henriette Braun

EXECUTIVE ASSISTANT View Details
Dr. Lea Bogner

Dr. Lea Bogner

Project Manager View Details
INGEBORG NEUMANN

INGEBORG NEUMANN

MANAGING PARTNER

Ingeborg Neumann is a co-founder and Managing Director of Peppermint VenturePartners GmbH and Managing Partner of Peppermint Charité Biomedical Fund.

In 1997, she established the Peppermint Holding GmbH – a medium-sized industrial group based in Berlin. The Peppermint Group develops and produces high-end, innovative textiles for the fields of fashion, home textiles and technical textiles, with a staff of more than 750 employees, achieving worldwide sales of approx. EUR 90 million.
In addition, Neumann started up the first Peppermint Venture Capital Fund in the year 2000.

What’s more, Ingeborg Neumann serves on several supervisory boards and advisory committees; e.g. German Textile + Fashion Confederation (President), in the Federation of German industries (Vice President and Treasurer), in the Berlin water utility company (member of the Supervisory Board), in the association Friends of the National Gallery of Berlin (Member of the Management Board).

Ingeborg Neumann studied business economics in Münster and Munich. She has a degree in business and the German title of “Diplom-Kauffrau”.

Dr. Joachim Rautter

Dr. Joachim Rautter

MANAGING PARTNER

“We ask a lot of our companies, but we are always fair in our dealings with them.”

Joachim Rautter is a co-founder and Managing Director of Peppermint VenturePartners GmbH and Managing Partner of Peppermint Charité Biomedical Fund.

Prior to the launch of Peppermint VenturePartners, he was Investment Director at Peppermint Holding GmbH. There he was responsible for the investment activities of the Peppermint Venture Capital Fund. He has over 15 years of experience in the venture capital industry and was Chairman of the Supervisory Board of Scienion AG, as well as Chairman of the Advisory Board of JADO Technologies GmbH and Innolume GmbH. He is currently Chairman of the Board of CEVEC Pharmaceuticals GmbH and CellAct Pharma GmbH, and also serves on the Board of CAP-CMV GmbH, CryoTherapeutics GmbH and Labfolder GmbH.

Prior to joining Peppermint, he guided innovative start-ups in the field of start-up financing and entrepreneurial development. In addition, he was involved in key functions in the design and implementation of regional innovation strategies, e.g. at BioTOP Berlin-Brandenburg and the innovation concept of the German state of Brandenburg.

Joachim Rautter has a degree in physics and completed his PhD at the Max Volmer Institute for Biophysical Chemistry at the Technical University of Berlin.

Dr. Klaus Stöckemann

Dr. Klaus Stöckemann

Managing Partner

“When funding innovative ideas, you have to be bold enough to take the first step, even alone, and swim against the flow.”

Klaus Stöckemann is a co-founder and Managing Director of Peppermint VenturePartners GmbH and Managing Partner of Peppermint Charité Biomedical Fund.

Prior to the launch of Peppermint VenturePartners, he was a general partner in the international healthcare venture team of 3i plc. During the time at 3i he was responsible for more than 12 investments. His track record at 3i included not only IPOs of companies such as Epigenomics, Jerini and Santhera, but also the trade sales of Evotec Neuroscience, Amaxa and Elbion.

Prior to his tenure at 3i, Stöckemann held leading positions in research as well as in business development at major pharma corporations such Schering AG and ASTA Medica (a Degussa-Hüls group subsidiary).

Klaus Stöckemann was a member of the supervisory boards or boards of Combinature, Epigenomics, Jerini, Amaxa, Immatics, as well as IntelliDx and Zonare in the United States. He is currently the Chairman of the boards of Humedics GmbH, Emperra GmbH, Caterna Vision, and is a board member of Implandata Ophthalmic Products GmbH.

Stöckemann’s more than 14-year experience in the venture capital industry makes him an experienced venture capital investor.

He has a Ph.D in biology and pharmacology from the University of Mainz, as well as an MBA from WHU/Kellogg, Northwestern University in the United States.

Dr. Magnus Holm

Dr. Magnus Holm

Venture Partner

Magnus Holm has been fortifying Peppermint’s investment team as a venture partner since September 2012.

Holm has many years of operative experience in various executive positions in the medical technology industry. In addition to the development and clinical approval of medical products, his duties have also included business development, along with sales and marketing.

As General Manager for companies such as Biosense Webster, EMEA or Stereotaxis Inc. (USA), Holm made a decisive contribution towards the introduction of new, innovative products and technologies that quickly established themselves in clinical routines in the field of cardiology and electro-physiology (3-D electro-anatomical mapping of heart chambers, drug eluting stents and robot controls of interventional therapeutic heart catheters).

Besides his role as Venture Partner at PVP, Holm is the CEO of SWAT Medical AS, a cardiology focused early stage medial device company in Sweden and serves as a board member for Personal MedSystems GmbH in Germany.

Magnus Holm has a Master of Science in Biomedical Technology and a PhD in Medical Technology from the University of Lund (Sweden).

Dr. Markus Müschenich

Dr. Markus Müschenich

Venture Partner

Dr. Markus Müschenich is a specialist for Pediatrics and Adolescent Medicine, in addition to having a Master’s degree in Public Health (MPH). Since 2014, he has been a venture partner of PVP, and supports the PVP team as an expert for Digital Health in the evaluation and mentoring of early-stage companies.

Up to 2012, he was a member of the Management Board of the Sana Kliniken AG hospital group in Ismaning and previously a member of the Medical Management Board of the faith-based healthcare provider, Paul Gerhardt Diakonie, in Berlin. Since 2012, he has been a member of the Management Board of the German Association of Internet Medicine. As the founder of the think tank ConceptHealth, he is specialized in strategic foresight for medicine of the future.

In addition, Müschenich is Managing Partner and Co-Founder of FLYING HEALTH – the start-up factory. FLYING HEALTH assists health start-ups with an Internet medicine focus in their strategic development, company building and market entry.

SIMONE SCHÖPP

SIMONE SCHÖPP

CONTROLLING

Simone Schöpp joined Peppermint VenturePartners in January 2015. She supports our portfolio companies with her experiences in controlling and in the healthcare sector.

Prior to Peppermint she worked as Senior Financial Analyst with a pharmaceutical Contract Research Organisation first in Berlin and later in the US. Simone holds a Diploma in Business Administration from the HTW in Berlin.

Before and during her studies she gained professional experience in the research and in the finance department of an innovative biotech start-up, giving her a comprehensive understanding of the industry.

Henriette Braun

Henriette Braun

EXECUTIVE ASSISTANT

Henriette Braun has been working as the Assistant to the Managing Directors of PVP since December 2012.

Previously, she worked for several years as an executive assistant in the logistics field and as a scientific project team member in an environmental engineering firm.

Braun has a degree in business with a specialization in the fields of Environmental Management and Management of Small to Medium-Size Enterprises (SMEs).

Dr. Lea Bogner

Dr. Lea Bogner

Project Manager

Lea Bogner is working as a project manager for Peppermint VenturePartners since May 2016. During her PhD at the Department of Physics of the Freie Universität Berlin and at the Fritz Haber Institute of the Max-Planck Society she was engaged in elementary electronic processes in organic solar cells and LEDs.
Prior to this Lea Bogner graduated in chemistry from the Freie Universität Berlin.

expert-panel

Expert Panel

The investment team is supported by established experts from research and industry. They assist PVP in the international benchmarking of investment opportunities and help new portfolio companies by providing strategic consulting, serving on advisory boards or in management.


DR. TOM ALBERT

Insurance and Health Care Expert

Albert is Managing Director at “Meine-Gesundheit-Services GmbH”, a company offering secure e-portals and apps managing interactions between patients, doctors / clinics and private health insurers in a fully digital way. The offerings facilitate billing and administrative processes for privately insured patients and provide a wide range of mobile health services such as medication services, electronic patient records and diagnosis-related coachings.

Before that he held different positions at AXA Krankenversicherung AG.  Albert was Head of Health Strategy from  2012 to 2016, responsible for expanding and further developing the health insurance business and for exploring new business areas. From 2010 to 2012 Albert headed the “Aktiver Gesundheitsservice” [active health service] department for chronic and seriously ill policy holders and was responsible for developing and expanding care programmes. At the health insurance companies AXA/DBV-Winterthur he was project leader from 2007 to 2010 in the area of integration and data migration.

After studying theoretical physics at the University of Bonn and subsequently receiving a doctorate in mathematical physics, Albert worked from 2001 to 2007 as a management consultant at Boston Consulting Group, with a special focus in the area of insurance.


Prof. Dr. Maurice Buchbinder

Expert for Cardiovascular Diseases
Buchbinder studied medicine at the McGill University in Montreal, Canada. After completing his studies, he specialized at Stanford University in the treatment of cardiovascular diseases, and accomplished groundbreaking work in the new field of interventional cardiology.

Dr. Buchbinder played an integral role in the development of many medical products that are used routinely today in the practice of interventional medicine.

For many years, his interest has been dedicated to the improvement of treatment of patients with diseases of the coronary arteries. In the recent past, Buchbinder launched a series of innovations involving the use of percutaneous treatment of various illnesses of the heart valves, as a replacement of invasive surgical open-heart procedures.

Dr. Buchbinder is the co-founder of several successful companies, including the portfolio company CryoTherapeutics. He assists PVP with his clinical expertise and his knowledge in the area of medical start-ups in interventional cardiology.


Prof. Dr. Carl Erb

Expert for Ophthalmology

Erb studied medicine at the Ruhr-Universität Bochum, Freie Universität Berlin and at the Royal Preston Hospital, England.

From 2005 to 2011, he was head physician in the ophthalmology department at the Schlosspark-Klinik Berlin. Since 2006, Erb has also been a special guest professor at the Charité Berlin.

Since 2002, he has been actively involved in the German Ophthalmology Society, where he has also served as Vice-President of the section on glaucoma since 2010.

Since 2011, Erb has been working at the eye clinic at Wittenbergplatz in Berlin as a specialist for cataract and glaucoma surgery.

Dr. Wolfgang Götz

Expert for Minimal-Invasive Technologies
Götz is a heart surgeon with over 10 years of clinical experience. His main area of interest is in the development of minimal-invasive technologies for the replacement of heart valves. He is the founder and Managing Director of Transcatheter Technologies GmbH in Regensburg, a company developing a new trans-catheter aorta valve.

PROF. DR. ANNETTE GRÜTERS-KIESLICH

Expert for Paediatrics and Endocrinology
In 1980, Grüters-Kieslich completed her medical studies at the Freie Universität Berlin and obtained her PhD in 1982. After beginning her residency in pediatrics, between 1982 and 1984 she worked on a DFG research fellowship in the field of perinatology at the University of California, Los Angeles. In 1998, she was appointed to a C3 professorship for pediatric endocrinology in the Medical Department of the Humboldt University of Berlin, and in 2004, she was appointed to a C4 chair for pediatric endocrinology.

Since 2005, she has been Medical Director of the Charité Gynecology, Perinatal, Pediatric and Adolescent Medicine with Perinatal Center and Human Genetics. Grüters-Kieslich’s main area of research is in the field of molecular pathogenesis of thyroid diseases and the pathophysiology of juvenile obesity.

DR. CHRISTINE KREINER

Expert for Medical Devices in Ophthalmology
Christine Kreiner studied pharmaceutical chemistry at the Ludwig‐Maximilians‐Universität in Munich and subsequently worked for several years as an assistant professor, and later as the research director of a pharmaceutical firm. In 1985, she launched her own company and has since founded and managed three firms in the healthcare field.

These companies were involved in the development, production, and worldwide sales of pharmaceuticals and medical products in the segments of ophthalmology and aesthetics. She led the first two companies, Adatomed and AcriTec, to revenues of more than EUR 20 million, and successfully sold them to Chiron (Adatomed) and Carl Zeiss (AcriTec).

In the year 2007, she established S&V Technologies in Hennigsdorf and BSC Medical Devices in Munich, in order to develop new biomaterials in the field of aesthetics and ophthalmology.
Kreiner is a member of several international medical societies and actively involved as a research consultant for various companies, along with the German state of Brandenburg. In addition, Kreiner has developed numerous patents.

 Dr. Fred Schaebsdau

Diagnostic Expert

Schaebsdau studied medicine at the University of Gießen and during his specialist training performed longer periods of residency in the urological departments at the University of Chicago, the Medical University of Hannover and the University of Freiburg. He is also licensed to practice medicine in the United States and Germany. While at the Medical University of Hannover, he conducted laboratory research projects funded by the German Research Foundation, earning his doctorate. In the year 1993, Schaebsdau earned his MBA from The Wharton School of the University of Pennsylvania.

He began his career at Eli Lilly Medical Devices Division (later Guidant) Cardiac Rhythm Management as Head of Sales & Marketing in Germany. Afterwards, he worked as Manager at The Mac Group (later Gemini Consulting), a strategy consultancy in Munich. Schaebsdau subsequently switched to Booz Allen Hamilton and led the global strategy projects in the pharmaceutical, medical technology and health-care industry.

For a group of investors, he established the BioScience Ventures Group, a venture capital company with a focus on “early stage” investments in the German biotechnology industry, and became its Managing Director. In the year 2004, Schaebsdau joined Abbott Diagnostics, where he held an executive position with increasing responsibility, both in the EMEA region and later in the global organisation of Abbott Diabetes Care. From 2009 to August 2015, Schaebsdau was Head of Global Strategy and Business Development at Roche Diabetes Care.

Mark Wächter

Mobile Strategy Expert

Mark Wächter is marketer with many years professional and leadership experience in the areas of Consumer Goods, Internet and Mobile Communications. In May 2005 he founded MWC.mobi, a worldwide active management consultancy focusing on Mobile Strategy Development and served clients in over 30 countries on all continents in the past years.

Mark is head of the Mobile Marketing Association (MMA) in Germany (locally known as BVDW Section Mobile) and member of MMAs Board of Directors. He is co-founder of MobileMonday and chairs the advisory board of Germany’s first Master Degree Program in Mobile Marketing at Leipzig School of Media. Mark is a Mobile Aficionado since the very beginning and became a globally well respected Mobile Media Evangelist and Strategist aka ‚Mr. Mobile‘, acting as advisor and mentor on many Mobile Initiatives.

In December 2015 Springer Gabler published his book ‚MOBILE STRATEGY‘. This has been chosen as basic compendium for the charismha study on Mobile Health Apps. Connected Health is a core competency of Mark. He organizes the world’s largest Medical Mobile Solutions award, the annual MEDICA App Competition. In May 2016 he co-initiated the global thinktank on Digital Health, FTR4H.

beirat

Advisory Board

The PVP Advisory Board supports the team as a discussion partner on questions regarding the strategic development of the portfolio. It consists of experienced managers in the healthcare field, clinical experts and successful companies.


Dr. Rolf Zettl
Johannes Schneider Littfeld
Dr. Bernd Wegener
portfolio

Portfolio

Caterna Vision GmbH
CEVEC Pharmaceuticals GmbH
CryoTherapeutics GmbH
EMPERRA GmbH E-Health Technologies
Humedics GmbH
Implandata Ophthalmic Products GmbH
Miracor Medical Systems GmbH
labfolder GmbH
the-peppermint-charite-biomedical-fund-cbf

The Peppermint Charité Biomedical Fund (CBF)

The Peppermint Charité Biomedical Fund (CBF-1) is an independent venture capital fund that was launched in November 2010.

Within the scope of cooperation with Charité – Universitätsmedizin Berlin, the CBF has privileged access to the network of the Charité and the international partners of the University Hospital. This cooperation is simultaneously harnessed for the evaluation of all investment opportunities. In association with PVP’s established network, encompassing additional first-rate medical research institutions, venture capital firms, as well as companies, high-caliber investment opportunities can be identified.
The CBF invests in start-ups and early-stage companies in the healthcare sector. These companies should already be able to demonstrate an initial “proof of concept” for their technology, their product or their business model. Investments are geared mainly towards early-stage medical devices as well as digital health companies addressing medical problems and markets with high growth potential. In addition, selective investments are also made in attractive pharma projects, e.g. platforms.  
partnerships

Partnerships

In addition to our own activities in fund management, we work very closely with other private and public venture funds, new instruments of validation funding, as well as with technology transfer agencies of the key German research foundation and universities. Currently, the most significant areas of collaboration for Peppermint VenturePartners include the Charité – Universitätsmedizin Berlin, the Charité Foundation and Helmholtz Association.


With the establishment of the Helmholtz Validation Fund (HVF) in the year 2011, the Helmholtz Association introduced a new financial instrument across several institutions, tapping funding from the Initiative and Networking Fund. The aim of the HVF is to close the existing gap between research findings and their marketable applications, as well as public research and private institutions. The funding levels from the Helmholtz Validation Fund range between 0.25 and 1 million euros per year. The idea is to evaluate new technologies in terms of their technical feasibility and to achieve a functioning prototype or initial positive pre-clinical validation. In order to ensure professional guidance according to industry and venture capital standards, a network of industry experts and project managers assists the team.

Peppermint VenturePartners has taken over the external fund management as an experienced early-stage investor.



press

Press.

press-contact
pvp-press-review

Press Reviews

news

News

update-pvp-newsletter

UPDATE – PVP Newsletter

The PVP team regularly publishes the so-called Update, the company newsletter, where trends and topics from the healthcare industry, entrepreneurs and new portfolio companies are introduced.


DOWNLOADS

  UPDATE Nr. 1 | Main focus: m-health

  UPDATE Nr. 2 | Main focus: eye diseases

  UPDATE Nr. 3 | Main focus: smart labs

  PORTFOLIO NEWS | The Journey from MedTech into Digital Health (October 2017)

Ihr Name / Your name (*)

Ihre E-Mail-Adresse / your email (*)

contact

CONTACT


Contact form

Your name (required)

Your email (required)

Your message

Adress

Peppermint VenturePartners GmbH

Neues Kranzler Eck
Kurfürstendamm 21
10719 Berlin
T: +49 30 59 00 64- 412
F: +49 30 59 00 64- 401
info@peppermint-vp.com

careers-at-pvp

CAREERS AT PVP


Intern (m/f)

We are regularly seeking student interns.

Your profile:

Your main course of studies should be one of the following: Chemistry, physics, medicine, biology, engineering or business. It is an advantage if you can already demonstrate experience based on internships, e.g. in the fields of innovation management and project assessment, project analysis and project controlling. Good skills in Office applications are a prerequisite.

Competencies:

Strong analytical skills are desired, as the nature of the work can be highly complex. As a small team, we expect a team-oriented work ethic, dependability, strong communication skills and self-initiative. Written and verbal fluency in German and English are a prerequisite.

IYour tasks:

  • Support in the maintenance of the deal flow database
  • Support in the due diligence process. This involves: Market and competitor analyses, references, interviews and written summaries of findings.
If you are interested, please contact:

Dr. Klaus Stöckemann

Tel. +49 30 590064 412

Peppermint VenturePartners GmbH
Kurfürstendamm 21
10719 Berlin, Germany

Email to Henriette Braun:
hb@peppermint-vp.com

 

imprint

Imprint

Peppermint VenturePartners GmbH
Kurfürstendamm 21
10719 Berlin

Sitz der Gesellschaft: Berlin
Registergericht: Berlin-Charlottenburg HRB 117003B
Finanzamt für Körperschaften I
Ust-Id-Nr. DE 263663009

Inhaltlich Verantwortlicher gemäß § 6 MDStV:

Ingeborg Neumann, Dr. Joachim Rautter, Dr. Klaus Stöckemann

Legal notice

Welcome to our website. If you continue to browse and use this website you are agreeing to comply with and be bound by the following terms and conditions of use, which together with our privacy policy govern [business name]’s relationship with you in relation to this website.

The term ‘Peppermint VenturePartners GmbH’ or ‘us’ or ‘we’ refers to the owner of the website whose registered office is Neues Kranzler Eck, Kurfürstendamm 21, 10719 Berlin. The term ‘you’ refers to the user or viewer of our website.

The use of this website is subject to the following terms of use:
The content of the pages of this website is for your general information and use only. It is subject to change without notice.

Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.

This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions.

All trade marks reproduced in this website which are not the property of, or licensed to, the operator are acknowledged on the website.

Unauthorised use of this website may give rise to a claim for damages and/or be a criminal offence.

From time to time this website may also include links to other websites. These links are provided for your convenience to provide further information. They do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s).

privacypolicy

Privacy Policy

Privacy Policy

We are very delighted that you have shown interest in our enterprise. Data protection is of a particularly high priority for the management of the Peppermint VenturePartners GmbH. The use of the Internet pages of the Peppermint VenturePartners GmbH is possible without any indication of personal data; however, if a data subject wants to use special enterprise services via our website, processing of personal data could become necessary. If the processing of personal data is necessary and there is no statutory basis for such processing, we generally obtain consent from the data subject.

The processing of personal data, such as the name, address, e-mail address, or telephone number of a data subject shall always be in line with the General Data Protection Regulation (GDPR), and in accordance with the country-specific data protection regulations applicable to the Peppermint VenturePartners GmbH. By means of this data protection declaration, our enterprise would like to inform the general public of the nature, scope, and purpose of the personal data we collect, use and process. Furthermore, data subjects are informed, by means of this data protection declaration, of the rights to which they are entitled.

As the controller, the Peppermint VenturePartners GmbH has implemented numerous technical and organizational measures to ensure the most complete protection of personal data processed through this website. However, Internet-based data transmissions may in principle have security gaps, so absolute protection may not be guaranteed. For this reason, every data subject is free to transfer personal data to us via alternative means, e.g. by telephone.

1. Definitions

The data protection declaration of the Peppermint VenturePartners GmbH is based on the terms used by the European legislator for the adoption of the General Data Protection Regulation (GDPR). Our data protection declaration should be legible and understandable for the general public, as well as our customers and business partners. To ensure this, we would like to first explain the terminology used.

In this data protection declaration, we use, inter alia, the following terms:

  • a)    Personal data

    Personal data means any information relating to an identified or identifiable natural person (“data subject”). An identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person.

  • b) Data subject

    Data subject is any identified or identifiable natural person, whose personal data is processed by the controller responsible for the processing.

  • c)    Processing

    Processing is any operation or set of operations which is performed on personal data or on sets of personal data, whether or not by automated means, such as collection, recording, organisation, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure or destruction.

  • d)    Restriction of processing

    Restriction of processing is the marking of stored personal data with the aim of limiting their processing in the future.

  • e)    Profiling

    Profiling means any form of automated processing of personal data consisting of the use of personal data to evaluate certain personal aspects relating to a natural person, in particular to analyse or predict aspects concerning that natural person’s performance at work, economic situation, health, personal preferences, interests, reliability, behaviour, location or movements.

  • f)     Pseudonymisation

    Pseudonymisation is the processing of personal data in such a manner that the personal data can no longer be attributed to a specific data subject without the use of additional information, provided that such additional information is kept separately and is subject to technical and organisational measures to ensure that the personal data are not attributed to an identified or identifiable natural person.

  • g)    Controller or controller responsible for the processing

    Controller or controller responsible for the processing is the natural or legal person, public authority, agency or other body which, alone or jointly with others, determines the purposes and means of the processing of personal data; where the purposes and means of such processing are determined by Union or Member State law, the controller or the specific criteria for its nomination may be provided for by Union or Member State law.

  • h)    Processor

    Processor is a natural or legal person, public authority, agency or other body which processes personal data on behalf of the controller.

  • i)      Recipient

    Recipient is a natural or legal person, public authority, agency or another body, to which the personal data are disclosed, whether a third party or not. However, public authorities which may receive personal data in the framework of a particular inquiry in accordance with Union or Member State law shall not be regarded as recipients; the processing of those data by those public authorities shall be in compliance with the applicable data protection rules according to the purposes of the processing.

  • j)      Third party

    Third party is a natural or legal person, public authority, agency or body other than the data subject, controller, processor and persons who, under the direct authority of the controller or processor, are authorised to process personal data.

  • k)    Consent

    Consent of the data subject is any freely given, specific, informed and unambiguous indication of the data subject’s wishes by which he or she, by a statement or by a clear affirmative action, signifies agreement to the processing of personal data relating to him or her.

2. Name and Address of the controller

Controller for the purposes of the General Data Protection Regulation (GDPR), other data protection laws applicable in Member states of the European Union and other provisions related to data protection is:

Peppermint VenturePartners GmbH

Kurfürstendamm 21
10719 Berlin-Germany

Phone: +49 30 59 00 64- 412
Email: info@peppermint-vp.com
Website: peppermint-vp.com

3. Cookies

The Internet pages of the Peppermint VenturePartners GmbH use cookies. Cookies are text files that are stored in a computer system via an Internet browser.

Many Internet sites and servers use cookies. Many cookies contain a so-called cookie ID. A cookie ID is a unique identifier of the cookie. It consists of a character string through which Internet pages and servers can be assigned to the specific Internet browser in which the cookie was stored. This allows visited Internet sites and servers to differentiate the individual browser of the dats subject from other Internet browsers that contain other cookies. A specific Internet browser can be recognized and identified using the unique cookie ID.

Through the use of cookies, the Peppermint VenturePartners GmbH can provide the users of this website with more user-friendly services that would not be possible without the cookie setting.

By means of a cookie, the information and offers on our website can be optimized with the user in mind. Cookies allow us, as previously mentioned, to recognize our website users. The purpose of this recognition is to make it easier for users to utilize our website. The website user that uses cookies, e.g. does not have to enter access data each time the website is accessed, because this is taken over by the website, and the cookie is thus stored on the user’s computer system. Another example is the cookie of a shopping cart in an online shop. The online store remembers the articles that a customer has placed in the virtual shopping cart via a cookie.

The data subject may, at any time, prevent the setting of cookies through our website by means of a corresponding setting of the Internet browser used, and may thus permanently deny the setting of cookies. Furthermore, already set cookies may be deleted at any time via an Internet browser or other software programs. This is possible in all popular Internet browsers. If the data subject deactivates the setting of cookies in the Internet browser used, not all functions of our website may be entirely usable.

4. Collection of general data and information

The website of the Peppermint VenturePartners GmbH collects a series of general data and information when a data subject or automated system calls up the website. This general data and information are stored in the server log files. Collected may be (1) the browser types and versions used, (2) the operating system used by the accessing system, (3) the website from which an accessing system reaches our website (so-called referrers), (4) the sub-websites, (5) the date and time of access to the Internet site, (6) an Internet protocol address (IP address), (7) the Internet service provider of the accessing system, and (8) any other similar data and information that may be used in the event of attacks on our information technology systems.

When using these general data and information, the Peppermint VenturePartners GmbH does not draw any conclusions about the data subject. Rather, this information is needed to (1) deliver the content of our website correctly, (2) optimize the content of our website as well as its advertisement, (3) ensure the long-term viability of our information technology systems and website technology, and (4) provide law enforcement authorities with the information necessary for criminal prosecution in case of a cyber-attack. Therefore, the Peppermint VenturePartners GmbH analyzes anonymously collected data and information statistically, with the aim of increasing the data protection and data security of our enterprise, and to ensure an optimal level of protection for the personal data we process. The anonymous data of the server log files are stored separately from all personal data provided by a data subject.

5. Contact possibility via the website

The website of the Peppermint VenturePartners GmbH contains information that enables a quick electronic contact to our enterprise, as well as direct communication with us, which also includes a general address of the so-called electronic mail (e-mail address). If a data subject contacts the controller by e-mail or via a contact form, the personal data transmitted by the data subject are automatically stored. Such personal data transmitted on a voluntary basis by a data subject to the data controller are stored for the purpose of processing or contacting the data subject. There is no transfer of this personal data to third parties.

6. Routine erasure and blocking of personal data

The data controller shall process and store the personal data of the data subject only for the period necessary to achieve the purpose of storage, or as far as this is granted by the European legislator or other legislators in laws or regulations to which the controller is subject to.

If the storage purpose is not applicable, or if a storage period prescribed by the European legislator or another competent legislator expires, the personal data are routinely blocked or erased in accordance with legal requirements.

7. Rights of the data subject

  • a) Right of confirmation

    Each data subject shall have the right granted by the European legislator to obtain from the controller the confirmation as to whether or not personal data concerning him or her are being processed. If a data subject wishes to avail himself of this right of confirmation, he or she may, at any time, contact any employee of the controller.

  • b) Right of access

    Each data subject shall have the right granted by the European legislator to obtain from the controller free information about his or her personal data stored at any time and a copy of this information. Furthermore, the European directives and regulations grant the data subject access to the following information:

    • the purposes of the processing;
    • the categories of personal data concerned;
    • the recipients or categories of recipients to whom the personal data have been or will be disclosed, in particular recipients in third countries or international organisations;
    • where possible, the envisaged period for which the personal data will be stored, or, if not possible, the criteria used to determine that period;
    • the existence of the right to request from the controller rectification or erasure of personal data, or restriction of processing of personal data concerning the data subject, or to object to such processing;
    • the existence of the right to lodge a complaint with a supervisory authority;
    • where the personal data are not collected from the data subject, any available information as to their source;
    • the existence of automated decision-making, including profiling, referred to in Article 22(1) and (4) of the GDPR and, at least in those cases, meaningful information about the logic involved, as well as the significance and envisaged consequences of such processing for the data subject.

    Furthermore, the data subject shall have a right to obtain information as to whether personal data are transferred to a third country or to an international organisation. Where this is the case, the data subject shall have the right to be informed of the appropriate safeguards relating to the transfer.

    If a data subject wishes to avail himself of this right of access, he or she may, at any time, contact any employee of the controller.

  • c) Right to rectification

    Each data subject shall have the right granted by the European legislator to obtain from the controller without undue delay the rectification of inaccurate personal data concerning him or her. Taking into account the purposes of the processing, the data subject shall have the right to have incomplete personal data completed, including by means of providing a supplementary statement.

    If a data subject wishes to exercise this right to rectification, he or she may, at any time, contact any employee of the controller.

  • d) Right to erasure (Right to be forgotten)

    Each data subject shall have the right granted by the European legislator to obtain from the controller the erasure of personal data concerning him or her without undue delay, and the controller shall have the obligation to erase personal data without undue delay where one of the following grounds applies, as long as the processing is not necessary:

    • The personal data are no longer necessary in relation to the purposes for which they were collected or otherwise processed.
    • The data subject withdraws consent to which the processing is based according to point (a) of Article 6(1) of the GDPR, or point (a) of Article 9(2) of the GDPR, and where there is no other legal ground for the processing.
    • The data subject objects to the processing pursuant to Article 21(1) of the GDPR and there are no overriding legitimate grounds for the processing, or the data subject objects to the processing pursuant to Article 21(2) of the GDPR.
    • The personal data have been unlawfully processed.
    • The personal data must be erased for compliance with a legal obligation in Union or Member State law to which the controller is subject.
    • The personal data have been collected in relation to the offer of information society services referred to in Article 8(1) of the GDPR.

    If one of the aforementioned reasons applies, and a data subject wishes to request the erasure of personal data stored by the Peppermint VenturePartners GmbH, he or she may, at any time, contact any employee of the controller. An employee of Peppermint VenturePartners GmbH shall promptly ensure that the erasure request is complied with immediately.

    Where the controller has made personal data public and is obliged pursuant to Article 17(1) to erase the personal data, the controller, taking account of available technology and the cost of implementation, shall take reasonable steps, including technical measures, to inform other controllers processing the personal data that the data subject has requested erasure by such controllers of any links to, or copy or replication of, those personal data, as far as processing is not required. An employees of the Peppermint VenturePartners GmbH will arrange the necessary measures in individual cases.

  • e) Right of restriction of processing

    Each data subject shall have the right granted by the European legislator to obtain from the controller restriction of processing where one of the following applies:

    • The accuracy of the personal data is contested by the data subject, for a period enabling the controller to verify the accuracy of the personal data.
    • The processing is unlawful and the data subject opposes the erasure of the personal data and requests instead the restriction of their use instead.
    • The controller no longer needs the personal data for the purposes of the processing, but they are required by the data subject for the establishment, exercise or defence of legal claims.
    • The data subject has objected to processing pursuant to Article 21(1) of the GDPR pending the verification whether the legitimate grounds of the controller override those of the data subject.

    If one of the aforementioned conditions is met, and a data subject wishes to request the restriction of the processing of personal data stored by the Peppermint VenturePartners GmbH, he or she may at any time contact any employee of the controller. The employee of the Peppermint VenturePartners GmbH will arrange the restriction of the processing.

  • f) Right to data portability

    Each data subject shall have the right granted by the European legislator, to receive the personal data concerning him or her, which was provided to a controller, in a structured, commonly used and machine-readable format. He or she shall have the right to transmit those data to another controller without hindrance from the controller to which the personal data have been provided, as long as the processing is based on consent pursuant to point (a) of Article 6(1) of the GDPR or point (a) of Article 9(2) of the GDPR, or on a contract pursuant to point (b) of Article 6(1) of the GDPR, and the processing is carried out by automated means, as long as the processing is not necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller.

    Furthermore, in exercising his or her right to data portability pursuant to Article 20(1) of the GDPR, the data subject shall have the right to have personal data transmitted directly from one controller to another, where technically feasible and when doing so does not adversely affect the rights and freedoms of others.

    In order to assert the right to data portability, the data subject may at any time contact any employee of the Peppermint VenturePartners GmbH.

  • g) Right to object

    Each data subject shall have the right granted by the European legislator to object, on grounds relating to his or her particular situation, at any time, to processing of personal data concerning him or her, which is based on point (e) or (f) of Article 6(1) of the GDPR. This also applies to profiling based on these provisions.

    The Peppermint VenturePartners GmbH shall no longer process the personal data in the event of the objection, unless we can demonstrate compelling legitimate grounds for the processing which override the interests, rights and freedoms of the data subject, or for the establishment, exercise or defence of legal claims.

    If the Peppermint VenturePartners GmbH processes personal data for direct marketing purposes, the data subject shall have the right to object at any time to processing of personal data concerning him or her for such marketing. This applies to profiling to the extent that it is related to such direct marketing. If the data subject objects to the Peppermint VenturePartners GmbH to the processing for direct marketing purposes, the Peppermint VenturePartners GmbH will no longer process the personal data for these purposes.

    In addition, the data subject has the right, on grounds relating to his or her particular situation, to object to processing of personal data concerning him or her by the Peppermint VenturePartners GmbH for scientific or historical research purposes, or for statistical purposes pursuant to Article 89(1) of the GDPR, unless the processing is necessary for the performance of a task carried out for reasons of public interest.

    In order to exercise the right to object, the data subject may contact any employee of the Peppermint VenturePartners GmbH. In addition, the data subject is free in the context of the use of information society services, and notwithstanding Directive 2002/58/EC, to use his or her right to object by automated means using technical specifications.

  • h) Automated individual decision-making, including profiling

    Each data subject shall have the right granted by the European legislator not to be subject to a decision based solely on automated processing, including profiling, which produces legal effects concerning him or her, or similarly significantly affects him or her, as long as the decision (1) is not is necessary for entering into, or the performance of, a contract between the data subject and a data controller, or (2) is not authorised by Union or Member State law to which the controller is subject and which also lays down suitable measures to safeguard the data subject’s rights and freedoms and legitimate interests, or (3) is not based on the data subject’s explicit consent.

    If the decision (1) is necessary for entering into, or the performance of, a contract between the data subject and a data controller, or (2) it is based on the data subject’s explicit consent, the Peppermint VenturePartners GmbH shall implement suitable measures to safeguard the data subject’s rights and freedoms and legitimate interests, at least the right to obtain human intervention on the part of the controller, to express his or her point of view and contest the decision.

    If the data subject wishes to exercise the rights concerning automated individual decision-making, he or she may, at any time, contact any employee of the Peppermint VenturePartners GmbH.

  • i) Right to withdraw data protection consent

    Each data subject shall have the right granted by the European legislator to withdraw his or her consent to processing of his or her personal data at any time.

    If the data subject wishes to exercise the right to withdraw the consent, he or she may, at any time, contact any employee of the Peppermint VenturePartners GmbH.

8. Data protection for applications and the application procedures

The data controller shall collect and process the personal data of applicants for the purpose of the processing of the application procedure. The processing may also be carried out electronically. This is the case, in particular, if an applicant submits corresponding application documents by e-mail or by means of a web form on the website to the controller. If the data controller concludes an employment contract with an applicant, the submitted data will be stored for the purpose of processing the employment relationship in compliance with legal requirements. If no employment contract is concluded with the applicant by the controller, the application documents shall be automatically erased two months after notification of the refusal decision, provided that no other legitimate interests of the controller are opposed to the erasure. Other legitimate interest in this relation is, e.g. a burden of proof in a procedure under the General Equal Treatment Act (AGG).

9. Data protection provisions about the application and use of Google Analytics (with anonymization function)

On this website, the controller has integrated the component of Google Analytics (with the anonymizer function). Google Analytics is a web analytics service. Web analytics is the collection, gathering, and analysis of data about the behavior of visitors to websites. A web analysis service collects, inter alia, data about the website from which a person has come (the so-called referrer), which sub-pages were visited, or how often and for what duration a sub-page was viewed. Web analytics are mainly used for the optimization of a website and in order to carry out a cost-benefit analysis of Internet advertising.

The operator of the Google Analytics component is Google Inc., 1600 Amphitheatre Pkwy, Mountain View, CA 94043-1351, United States.

For the web analytics through Google Analytics the controller uses the application “_gat. _anonymizeIp”. By means of this application the IP address of the Internet connection of the data subject is abridged by Google and anonymised when accessing our websites from a Member State of the European Union or another Contracting State to the Agreement on the European Economic Area.

The purpose of the Google Analytics component is to analyze the traffic on our website. Google uses the collected data and information, inter alia, to evaluate the use of our website and to provide online reports, which show the activities on our websites, and to provide other services concerning the use of our Internet site for us.

Google Analytics places a cookie on the information technology system of the data subject. The definition of cookies is explained above. With the setting of the cookie, Google is enabled to analyze the use of our website. With each call-up to one of the individual pages of this Internet site, which is operated by the controller and into which a Google Analytics component was integrated, the Internet browser on the information technology system of the data subject will automatically submit data through the Google Analytics component for the purpose of online advertising and the settlement of commissions to Google. During the course of this technical procedure, the enterprise Google gains knowledge of personal information, such as the IP address of the data subject, which serves Google, inter alia, to understand the origin of visitors and clicks, and subsequently create commission settlements.

The cookie is used to store personal information, such as the access time, the location from which the access was made, and the frequency of visits of our website by the data subject. With each visit to our Internet site, such personal data, including the IP address of the Internet access used by the data subject, will be transmitted to Google in the United States of America. These personal data are stored by Google in the United States of America. Google may pass these personal data collected through the technical procedure to third parties.

The data subject may, as stated above, prevent the setting of cookies through our website at any time by means of a corresponding adjustment of the web browser used and thus permanently deny the setting of cookies. Such an adjustment to the Internet browser used would also prevent Google Analytics from setting a cookie on the information technology system of the data subject. In addition, cookies already in use by Google Analytics may be deleted at any time via a web browser or other software programs.

In addition, the data subject has the possibility of objecting to a collection of data that are generated by Google Analytics, which is related to the use of this website, as well as the processing of this data by Google and the chance to preclude any such. For this purpose, the data subject must download a browser add-on under the link https://tools.google.com/dlpage/gaoptout and install it. This browser add-on tells Google Analytics through a JavaScript, that any data and information about the visits of Internet pages may not be transmitted to Google Analytics. The installation of the browser add-ons is considered an objection by Google. If the information technology system of the data subject is later deleted, formatted, or newly installed, then the data subject must reinstall the browser add-ons to disable Google Analytics. If the browser add-on was uninstalled by the data subject or any other person who is attributable to their sphere of competence, or is disabled, it is possible to execute the reinstallation or reactivation of the browser add-ons.

Further information and the applicable data protection provisions of Google may be retrieved under https://www.google.com/intl/en/policies/privacy/ and under http://www.google.com/analytics/terms/us.html. Google Analytics is further explained under the following Link https://www.google.com/analytics/.

10. Data protection provisions about the application and use of LinkedIn

The controller has integrated components of the LinkedIn Corporation on this website. LinkedIn is a web-based social network that enables users with existing business contacts to connect and to make new business contacts. Over 400 million registered people in more than 200 countries use LinkedIn. Thus, LinkedIn is currently the largest platform for business contacts and one of the most visited websites in the world.

The operating company of LinkedIn is LinkedIn Corporation, 2029 Stierlin Court Mountain View, CA 94043, UNITED STATES. For privacy matters outside of the UNITED STATES LinkedIn Ireland, Privacy Policy Issues, Wilton Plaza, Wilton Place, Dublin 2, Ireland, is responsible.

With each call-up to one of the individual pages of this Internet site, which is operated by the controller and on which a LinkedIn component (LinkedIn plug-in) was integrated, the Internet browser on the information technology system of the data subject is automatically prompted to the download of a display of the corresponding LinkedIn component of LinkedIn. Further information about the LinkedIn plug-in may be accessed under https://developer.linkedin.com/plugins. During the course of this technical procedure, LinkedIn gains knowledge of what specific sub-page of our website was visited by the data subject.

If the data subject is logged in at the same time on LinkedIn, LinkedIn detects with every call-up to our website by the data subject—and for the entire duration of their stay on our Internet site—which specific sub-page of our Internet page was visited by the data subject. This information is collected through the LinkedIn component and associated with the respective LinkedIn account of the data subject. If the data subject clicks on one of the LinkedIn buttons integrated on our website, then LinkedIn assigns this information to the personal LinkedIn user account of the data subject and stores the personal data.

LinkedIn receives information via the LinkedIn component that the data subject has visited our website, provided that the data subject is logged in at LinkedIn at the time of the call-up to our website. This occurs regardless of whether the person clicks on the LinkedIn button or not. If such a transmission of information to LinkedIn is not desirable for the data subject, then he or she may prevent this by logging off from their LinkedIn account before a call-up to our website is made.

LinkedIn provides under https://www.linkedin.com/psettings/guest-controls the possibility to unsubscribe from e-mail messages, SMS messages and targeted ads, as well as the ability to manage ad settings. LinkedIn also uses affiliates such as Eire, Google Analytics, BlueKai, DoubleClick, Nielsen, Comscore, Eloqua, and Lotame. The setting of such cookies may be denied under https://www.linkedin.com/legal/cookie-policy. The applicable privacy policy for LinkedIn is available under https://www.linkedin.com/legal/privacy-policy. The LinkedIn Cookie Policy is available under https://www.linkedin.com/legal/cookie-policy.

11. Data protection provisions about the application and use of Twitter

On this website, the controller has integrated components of Twitter. Twitter is a multilingual, publicly-accessible microblogging service on which users may publish and spread so-called ‘tweets,’ e.g. short messages, which are limited to 280 characters. These short messages are available for everyone, including those who are not logged on to Twitter. The tweets are also displayed to so-called followers of the respective user. Followers are other Twitter users who follow a user’s tweets. Furthermore, Twitter allows you to address a wide audience via hashtags, links or retweets.

The operating company of Twitter is Twitter, Inc., 1355 Market Street, Suite 900, San Francisco, CA 94103, UNITED STATES.

With each call-up to one of the individual pages of this Internet site, which is operated by the controller and on which a Twitter component (Twitter button) was integrated, the Internet browser on the information technology system of the data subject is automatically prompted to download a display of the corresponding Twitter component of Twitter. Further information about the Twitter buttons is available under https://about.twitter.com/de/resources/buttons. During the course of this technical procedure, Twitter gains knowledge of what specific sub-page of our website was visited by the data subject. The purpose of the integration of the Twitter component is a retransmission of the contents of this website to allow our users to introduce this web page to the digital world and increase our visitor numbers.

If the data subject is logged in at the same time on Twitter, Twitter detects with every call-up to our website by the data subject and for the entire duration of their stay on our Internet site which specific sub-page of our Internet page was visited by the data subject. This information is collected through the Twitter component and associated with the respective Twitter account of the data subject. If the data subject clicks on one of the Twitter buttons integrated on our website, then Twitter assigns this information to the personal Twitter user account of the data subject and stores the personal data.

Twitter receives information via the Twitter component that the data subject has visited our website, provided that the data subject is logged in on Twitter at the time of the call-up to our website. This occurs regardless of whether the person clicks on the Twitter component or not. If such a transmission of information to Twitter is not desirable for the data subject, then he or she may prevent this by logging off from their Twitter account before a call-up to our website is made.

The applicable data protection provisions of Twitter may be accessed under https://twitter.com/privacy?lang=en.

12. Legal basis for the processing

Art. 6(1) lit. a GDPR serves as the legal basis for processing operations for which we obtain consent for a specific processing purpose. If the processing of personal data is necessary for the performance of a contract to which the data subject is party, as is the case, for example, when processing operations are necessary for the supply of goods or to provide any other service, the processing is based on Article 6(1) lit. b GDPR. The same applies to such processing operations which are necessary for carrying out pre-contractual measures, for example in the case of inquiries concerning our products or services. Is our company subject to a legal obligation by which processing of personal data is required, such as for the fulfillment of tax obligations, the processing is based on Art. 6(1) lit. c GDPR.
In rare cases, the processing of personal data may be necessary to protect the vital interests of the data subject or of another natural person. This would be the case, for example, if a visitor were injured in our company and his name, age, health insurance data or other vital information would have to be passed on to a doctor, hospital or other third party. Then the processing would be based on Art. 6(1) lit. d GDPR.
Finally, processing operations could be based on Article 6(1) lit. f GDPR. This legal basis is used for processing operations which are not covered by any of the abovementioned legal grounds, if processing is necessary for the purposes of the legitimate interests pursued by our company or by a third party, except where such interests are overridden by the interests or fundamental rights and freedoms of the data subject which require protection of personal data. Such processing operations are particularly permissible because they have been specifically mentioned by the European legislator. He considered that a legitimate interest could be assumed if the data subject is a client of the controller (Recital 47 Sentence 2 GDPR).

13. The legitimate interests pursued by the controller or by a third party

Where the processing of personal data is based on Article 6(1) lit. f GDPR our legitimate interest is to carry out our business in favor of the well-being of all our employees and the shareholders.

14. Period for which the personal data will be stored

The criteria used to determine the period of storage of personal data is the respective statutory retention period. After expiration of that period, the corresponding data is routinely deleted, as long as it is no longer necessary for the fulfillment of the contract or the initiation of a contract.

15. Provision of personal data as statutory or contractual requirement; Requirement necessary to enter into a contract; Obligation of the data subject to provide the personal data; possible consequences of failure to provide such data

We clarify that the provision of personal data is partly required by law (e.g. tax regulations) or can also result from contractual provisions (e.g. information on the contractual partner).

Sometimes it may be necessary to conclude a contract that the data subject provides us with personal data, which must subsequently be processed by us. The data subject is, for example, obliged to provide us with personal data when our company signs a contract with him or her. The non-provision of the personal data would have the consequence that the contract with the data subject could not be concluded.

Before personal data is provided by the data subject, the data subject must contact any employee. The employee clarifies to the data subject whether the provision of the personal data is required by law or contract or is necessary for the conclusion of the contract, whether there is an obligation to provide the personal data and the consequences of non-provision of the personal data.

16. Existence of automated decision-making

As a responsible company, we do not use automatic decision-making or profiling.

17. Subscription to our newsletters

On the website of the Peppermint VenturePartners GmbH, users are given the opportunity to subscribe to our enterprise’s newsletter. The input mask used for this purpose determines what personal data are transmitted, as well as when the newsletter is ordered from the controller.

The Peppermint VenturePartners GmbH informs its customers and business partners regularly by means of a newsletter about enterprise offers. The enterprise’s newsletter may only be received by the data subject if (1) the data subject has a valid e-mail address and (2) the data subject registers for the newsletter shipping. A confirmation e-mail will be sent to the e-mail address registered by a data subject for the first time for newsletter shipping, for legal reasons, in the double opt-in procedure. This confirmation e-mail is used to prove whether the owner of the e-mail address as the data subject is authorized to receive the newsletter.

During the registration for the newsletter, we also store the IP address of the computer system assigned by the Internet service provider (ISP) and used by the data subject at the time of the registration, as well as the date and time of the registration. The collection of this data is necessary in order to understand the (possible) misuse of the e-mail address of a data subject at a later date, and it therefore serves the aim of the legal protection of the controller.

The personal data collected as part of a registration for the newsletter will only be used to send our newsletter. In addition, subscribers to the newsletter may be informed by e-mail, as long as this is necessary for the operation of the newsletter service or a registration in question, as this could be the case in the event of modifications to the newsletter offer, or in the event of a change in technical circumstances. There will be no transfer of personal data collected by the newsletter service to third parties. The subscription to our newsletter may be terminated by the data subject at any time. The consent to the storage of personal data, which the data subject has given for shipping the newsletter, may be revoked at any time. For the purpose of revocation of consent, a corresponding link is found in each newsletter. It is also possible to unsubscribe from the newsletter at any time directly on the website of the controller, or to communicate this to the controller in a different way.

6. Newsletter-Tracking

The newsletter of the Peppermint VenturePartners GmbH contains so-called tracking pixels. A tracking pixel is a miniature graphic embedded in such e-mails, which are sent in HTML format to enable log file recording and analysis. This allows a statistical analysis of the success or failure of online marketing campaigns. Based on the embedded tracking pixel, the Peppermint VenturePartners GmbH may see if and when an e-mail was opened by a data subject, and which links in the e-mail were called up by data subjects.

Such personal data collected in the tracking pixels contained in the newsletters are stored and analyzed by the controller in order to optimize the shipping of the newsletter, as well as to adapt the content of future newsletters even better to the interests of the data subject. These personal data will not be passed on to third parties. Data subjects are at any time entitled to revoke the respective separate declaration of consent issued by means of the double-opt-in procedure. After a revocation, these personal data will be deleted by the controller. The Peppermint VenturePartners GmbH automatically regards a withdrawal from the receipt of the newsletter as a revocation.

This Privacy Policy has been generated by the Privacy Policy Generator of the DGD – Your External DPO that was developed in cooperation with German Lawyers from WILDE BEUGER SOLMECKE, Cologne.

meet-us
news-press-releases

CEVEC and CellGenix cooperation leads to expansion of CellGenix cytokine portfolio with CAP®Go technology-derived TGF-ß1 for ex vivo cell culture

This portfolio expansion is the result of an ongoing collaboration and license agreement between CEVEC and CellGenix for the development and GMP production of selected cytokines for ex vivo cell culture therapy applications using CEVEC’s proprietary CAP®Go technology CEVEC’s CAP®Go technology enables CellGenix access to new cytokines and proteins

Read More

CEVEC to introduce new helper-free AAV packaging cell line for scalable stable gene therapy vector production at the Phacilitate Cell & Gene Therapy World Conference

Newly developed helper-free AAV packaging cell line provides unique solution for large-scale viral gene therapy vector production Easy and stable production processes, independent of transient transfection or helper virus Data from CEVEC’s successful proof-of-concept studies will be presented at the conference Cologne CEVEC Pharmaceuticals GmbH (CEVEC), the expert in

Read More

Miracor Medical raises € 25m

Funds will be used to support clinical and prepare commercial activities. Company relocates from Austria to Belgium Awans, Belgium and Vienna, Austria Miracor Medical Systems GmbH (Miracor Austria) and Miracor Medical SA (Miracor Medical) today announced the closing of € 25m as part of a Series D financing round. The

Read More

CEVEC has been granted a new CAP®Go technology patent and reinforces its leading role in production of recombinant proteins previously out of reach

New patent paves the way for further market expansion for CAP®Go expression platform Patent strengthens CEVEC’s unique position in producing recombinant proteins with tailor-made glycosylation Important milestone in establishing CAP®Go as the production standard for difficult-to- express recombinant glycoproteins Cologne, Germany CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the

Read More

labfolder selected for the Merck Accelerator

The Berlin start-up company labfolder, which is developing an electronic lab notebook, was selected out of 475 applicants worldwide to participate in the Accelerator program of the science and technology company Merck in Darmstadt for three months, starting today. Berlin and Darmstadt. Over the next three months, the Berlin startup

Read More

labfolder Expands to North America and Initiates Collaboration with the German Accelerator Life Sciences

Digital lab notebook platform company opens office in Cambridge to support U.S. growth and customer Relations BERLIN & CAMBRIDGE, Mass. labfolder and the German Accelerator Life Sciences (GALS), an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi), today announced the initiation of an extensive collaboration supporting

Read More

Peppermint VC realizes lucrative exit…

Berlin Peppermint VC realizes lucrative exit through the acquisition of next-generation chemotherapy agent CAP7.1 from German biotech CellAct by Mundipharma CellAct Pharma GmbH together with the Mundipharma global network has announced a new deal for the development and commercialization of smart chemotherapy (CAP7.1) with a total deal value exceeding 250

Read More

Appointment of Bent Johnsen as CEO for EMPERRA®

Potsdam EMPERRA®, specializing in digital health solutions for people living with diabetes, has appointed Mr. Bent Johnsen as Managing Director and CEO.  Mr. Johnsen, a Danish national, has an extensive international career in the health care sector and has lived and worked in multiple countries within Europe and the USA. 

Read More

Tackling the German Healthcare System

What are the latest trends in biotech and digital health funding and why is Germany still using fax machines in healthcare? a podcast by Tjasa Zajc with Klaus Stoeckemann, Managing Partner Part 1 Part 2

Read More

Emperra Wins the 2017 Game Changers Award for Digital Business Models

Potsdam Emperra GmbH, a start-up company based in Potsdam, Germany, has received the Finance Monthly’s 2017 Game Changers Award. The award is honouring Emperra for its new digital business models, which - based on innovative hardware - enable business revenue to be generated from digital solutions. The 2017 Game Changers

Read More

CEVEC and PlasmidFactory announce collaboration regarding adeno-associated virus (AAV) production

Parties intend to jointly enable AAV production in CEVEC's CAP(R)GT cells in combination with PlasmidFactory's broad AAV serotype plasmid portfolio Collaboration will significantly increase the value of CAP(R)GT for CEVEC customers by broadening the spectrum of available adeno-associated viral (AAV) vectors for gene therapy applications Cologne. CEVEC Pharmaceuticals GmbH

Read More

Humedics Announces Appointment of Karsten Damgaard-Iversen as CEO

Reinforcement of senior management team to leverage growth phase of Humedics Berlin. The Board of Humedics GmbH is pleased to announce a reinforcement of the senior team of the company with Karsten Damgaard-Iversen (MBA, BScEE), who will take up the role of CEO as of June 1, 2017. Erwin de

Read More

Biotech platform: Interview with CEVEC pharmaceuticals

The CSO of PVPs Portfolio Company CEVEC pharmaceuticals, Nicole Faust, was interviewed by labbiotech.eu - the leading digital media covering the European biotech industry - on CEVECS CAP Technology and it's fight against the Zika Virus. Read more:

Read More

CEVEC licenses CAP(R) technologies for the development and commercialization of vaccines against Zika Virus infections

Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development Cologne. CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with

Read More

Emperra Wins Prestigious Award With Innovative Diabetes Device

London. Emperra GmbH E-Health Technologies was announced Business Worldwide Magazine's (BWM) 2016 Company of the Year Award/Medical Device Industry Europe for its innovative diabetes management system. The device, known as ESYSTA® combines modern hardware (a blood glucose meter and insulin pen) with intelligent software in order to allow data to

Read More

home

Home